Skip to main navigation Skip to search Skip to main content

Erratum: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160)

  • David R. Spigel
  • , Martin J. Edelman
  • , Kenneth O’Byrne
  • , Luis Paz-Ares
  • , Simonetta Mocci
  • , See Phan
  • , David S. Shames
  • , Dustin Smith
  • , Virginia E. Paton
  • , Tony Mok
  • Sarah Cannon Research Institute
  • University of Maryland Cancer Center
  • Queensland University of Technology
  • Biomedical Network on Rare Diseases (CIBERER)
  • University of Seville
  • Genentech Incorporated
  • The Chinese University of Hong Kong

Research output: Contribution to journal › Comment/debate

Fingerprint

Dive into the research topics of 'Erratum: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160)'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry